Viking Therapeutics: Stock at $41.14 Following Modest Gain – Analysts Target $93.60 Average Price

Viking Therapeutics Inc. (VKTX) closed at $41.14 on July 9, 2026, posting a gain of $1.18 or 2.95 percent versus the previous day's close of $39.96. The California-based biotech company's stock traded in a range between $39.20 and $41.21 during the session, with trading volume of approximately 23,600 shares.

Analysts See Substantial Upside Potential

The analyst community is notably optimistic on Viking Therapeutics. Of 24 analysts covering the stock, 23 recommend buying: one analyst issues a "Strong Buy" rating, 22 issue "Buy" ratings, and only one issues a neutral "Hold" rating. There are no sell recommendations ("Sell" or "Strong Sell") as of July 9, 2026.

The average analyst price target stands at $93.60, with a median of $95.00. Price targets range from $83.00 (lowest) to $101.00 (highest). Should the average target be reached, this would represent a theoretical upside potential of approximately 128 percent from the current price.

Technical Indicators Show Solid Momentum

The Relative Strength Index (RSI) – a momentum indicator measuring overbought or oversold conditions – stood at 65.38 for Viking Therapeutics on July 8, 2026. An RSI between 30 and 70 is considered neutral, while values above 70 suggest an overbought market. In prior days, the RSI occasionally moved above 70: on July 7 it reached 74.67, on June 29 it hit 75.36, and on June 24 it reached 75.03, indicating strong upward momentum.

The recent cooling of the RSI below 70 can be interpreted as a normalization following a period of elevated buying activity, without the underlying momentum being lost.

Pipeline Focused on Metabolic Diseases

Viking Therapeutics is a clinical-stage biotech company developing novel therapies for metabolic and endocrine disorders. The centerpiece of its research pipeline is VK2809, an orally administered, tissue- and receptor-selective beta thyroid hormone receptor (TRß) agonist. This drug candidate is currently in Phase IIb trials for the treatment of non-alcoholic steatohepatitis (NASH) – a severe form of fatty liver disease with inflammation – as well as for non-alcoholic fatty liver disease (NAFLD) in biopsy-confirmed patients.

Additional pipeline candidates include VK5211, an oral, non-steroidal selective androgen receptor modulator (SARM), currently in Phase II trials for patients recovering from non-elective hip fracture surgery. VK0612, an oral drug candidate for Type 2 diabetes, is on the verge of entering Phase IIb trials. Additionally, the company is developing VK0214, another oral therapeutic.

Perspective for Investors

The substantial gap between the current price ($41.14) and the average analyst price target ($93.60) reflects typical valuation dynamics in the biotech sector. Clinical-stage companies are often valued based on the success of their pipelines – positive study results or regulatory milestones can drive significant price movements, while setbacks carry corresponding risks.

The broad buy recommendation from analysts suggests confidence in the clinical programs, particularly VK2809 for NASH and NAFLD. NASH is considered a growing market with high medical need, as only few approved therapies currently exist. However, investors should consider the inherent risks of clinical development: Phase II trials are still far from market approval, and success is not guaranteed.

Trading Data Overview

• Closing price on July 9, 2026: $41.14
• Change: +$1.18 (+2.95 percent)
• Daily range: $39.20 to $41.21
• Trading volume: 23,556 shares
• RSI (July 8, 2026): 65.38
• Average price target: $93.60
• Analyst consensus: 1 Strong Buy, 22 Buy, 1 Hold

Viking Therapeutics is listed on a US exchange and trades in US dollars. For investors in the DACH region, currency risk should be considered when investing in USD-denominated securities. The company is headquartered in California and focuses on developing innovative therapeutic approaches for diseases that currently have limited treatment options.